Shikari® (Q-GOL) Golimumab ELISA
GOL-FD-SIM
Enzyme immunoassay for the quantitative determination of Golimumab (Simponi®) in serum and plasma.
This kit has been especially developed for the quantitative determination of golimumab in serum and plasma samples between the Cmin and Cmax range of concentrations.
Golimumab Drug Bank Accession Number is DB06674.
Golimumab is a TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 20 |
| Total Time (min) | 70 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 10 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
| # | File | Action |
|---|---|---|
| Instructions For Use | Download | |
| Safety Data Sheet (SDS) | Download | |
| Validation Report | Download |
Publications with this drug
| # | File | Action |
|---|---|---|
| Tawa, Hideki, et al. "Therapeutic drug monitoring of golimumab for the prediction of long-term clinical remission in patients with ulcerative colitis." Digestion 103.5 (2022): 329-338. | Visit Link |